Clinical Trials on Differentiated Thyroid Carcinoma (DTC)

Total 570 results

Peking University Cancer Hospital & Institute

Completed

Compare the Aesthetic Effect of Different Thyroidectomies

Differentiated Thyroid Carcinoma (DTC)
Eisai Korea Inc.

Completed

Post-Marketing Surveillance of Lenvima in Korean Patients

Differentiated Thyroid Carcinoma (DTC)

Korea, Republic of
European Organisation for Research and Treatment...

Completed

Nintedanib(BIBF1120) in Thyroid Cancer

Differentiated Thyroid Cancer (DTC) | Medullary Thyroid Cancer (MTC)

France, Belgium, Denmark, Italy, Netherlands, Germany, Poland, Spain, United Kingdom
Thomas Jefferson University

Active, not recruiting

A Phase II Trial of Cabozantinib for the Treatment of Radioiodine (RAI)-Refractory Differentiated Thyroid Carcinoma (DTC) in the First-line Setting

Differentiated Thyroid Cancer (DTC) | Poorly Differentiated Thyroid Cancer

United States
National Cancer Institute (NCI)

Terminated

CUDC-907 Treatment in People With Metastatic and Locally Advanced Thyroid Cancer

Thyroid Neoplasms | Differentiated Thyroid Cancer | Poorly Differentiated and Undifferentiated Thyroid Cancer

United States
Eisai Co., Ltd.

Completed

A Trial of Lenvatinib (E7080) in Radioiodine (131 I)-Refractory Differentiated Thyroid Cancer in China

Differentiated Thyroid Cancer (DTC)

China
Yansong Lin

Active, not recruiting

Study on the Treatment of Differentiated Thyroid Carcinoma With Anlotinib

DTC - Differentiated Thyroid Cancer

China
Providence Health & Services

Recruiting

Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer

BRAF V600E Mutation Present | Stage IV Differentiated Thyroid Gland Carcinoma AJCC v8 | Refractory Thyroid Gland Carcinoma | Metastatic Thyroid Gland Carcinoma | BRAF NP_004324.2:p.V600M | Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v8 | Stage IVB Differentiated Thyroid Gland Carcinoma...

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Completed

Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC)

Poorly Differentiated Thyroid Gland Carcinoma | Recurrent Differentiated Thyroid Gland Carcinoma | Columnar Cell Variant Thyroid Gland Papillary Carcinoma | Follicular Variant Thyroid Gland Papillary Carcinoma | Metastatic Thyroid Gland Follicular Carcinoma | Metastatic Thyroid Gland Papillary... and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer

Poorly Differentiated Thyroid Gland Carcinoma | Refractory Differentiated Thyroid Gland Carcinoma | Refractory Thyroid Gland Carcinoma | Follicular Variant Thyroid Gland Papillary Carcinoma | Tall Cell Variant Thyroid Gland Papillary Carcinoma | Differentiated Thyroid Gland Carcinoma | Thyroid... and other conditions

United States
National Cancer Institute (NCI)

Completed

Pazopanib Hydrochloride in Treating Patients With Advanced Thyroid Cancer

Recurrent Thyroid Gland Carcinoma | Thyroid Gland Anaplastic Carcinoma | Stage III Differentiated Thyroid Gland Carcinoma AJCC v7 | Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v7 | Stage IVB Differentiated Thyroid Gland Carcinoma AJCC v7 | Stage IVC Differentiated Thyroid Gland Carcinoma... and other conditions

United States, Taiwan, Australia, Singapore, China
Beijing Scitech-Mq Pharmaceuticals Limited

Recruiting

Study of ST-1898 in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Cancer

Differentiated Thyroid Carcinoma

China
Eisai Limited
Merck Sharp & Dohme LLC

Completed

Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma

Osteosarcoma | Tumors | Differentiated Thyroid Cancer (DTC) | Solid Malignant Tumors

Spain, Italy, United States, United Kingdom, France, Germany
University of Pennsylvania

Completed

Phase II Trial of Sorafenib (Nexavar) in Patients With Advanced Thyroid Cancer

Metastatic Medullary Thyroid Cancer | Metastatic Differentiated Thyroid Cancer | Metastatic Anaplastic Thyroid Cancer | Metastatic Poorly Differentiated Thyroid Cancer

United States
H. Lee Moffitt Cancer Center and Research Institute

Terminated

Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer

Thyroid Cancer, Medullary | Thyroid Cancer | Papillary Thyroid Cancer | Differentiated Thyroid Cancer | Poorly Differentiated Thyroid Gland Carcinoma | Follicular Thyroid Cancer

United States
University of Texas Southwestern Medical Center
Novartis

Withdrawn

Ceritinib in Mutation and Oncogene Directed Therapy in Thyroid Cancer

Metastatic Anaplastic Thyroid Cancer | Locally Advanced Anaplastic, Undifferentiated Thyroid Cancer

United States
University of Wuerzburg
Deutsche Krebshilfe e.V., Bonn (Germany)

Recruiting

I-124 PET/CT Based Remnant Radioiodine Ablation Decision Concept in Differentiated Thyroid Cancer (CLERAD-PROBE)

Differentiated Thyroid Carcinoma

Germany
Peking Union Medical College Hospital

Not yet recruiting

Study of Anlotinib in Patients With Radioiodine Refractory Differentiated Thyroid Cancer

Locally Advanced or Metastatic Radioiodine-refractory Differentiated Thyroid Carcinoma

China
Tianjin Medical University Cancer Institute and...

Unknown

Phase 2 Trial of Apatinib Mesylate in Locally Advanced/Metastatic Differentiated Thyroid Carcinoma

Differentiated Thyroid Carcinoma

China
Oncology Institute of Southern Switzerland

Completed

OnT4-Thyroglobulin Assay Before rhTSH-Aided Radioiodine Ablation

Differentiated Thyroid Carcinoma
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Unknown

PLD Combined With Cisplatin in the Treatment of Advanced Poorly Differentiated Thyroid Carcinoma

Poorly Differentiated Thyroid Carcinoma

China
National Institute of Diabetes and Digestive and...

Completed

Effect of Lithium Carbonate on Low-Dose Radioiodine Therapy in Early Thyroid Cancer

Thyroid Cancer | Differentiated Thyroid Carcinoma

United States
Grupo Español de Tratamiento de Tumores de Cabeza...

Active, not recruiting

Spanish Study for Molecular Characterization of Thyroid Carcinoma (MOLTHY)

Differentiated Thyroid Carcinoma | Medullary Thyroid Carcinoma

Spain
Saint Petersburg State University, Russia

Withdrawn

Pembrolizumab and Lenvatinib/Chemotherapy for Poorly Differentiated/Anaplastic Thyroid Cancer

Poorly Differentiated Thyroid Gland Carcinoma | Metastatic Thyroid Gland Carcinoma | Thyroid Gland Anaplastic Carcinoma by AJCC V8 Stage

Russian Federation
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Lenvatinib and Pembrolizumab for the Treatment of Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer

Poorly Differentiated Thyroid Gland Carcinoma | Thyroid Gland Squamous Cell Carcinoma | Unresectable Thyroid Gland Carcinoma | Metastatic Thyroid Gland Carcinoma | Stage IVB Thyroid Gland Anaplastic Carcinoma AJCC v8 | Stage IVC Thyroid Gland Anaplastic Carcinoma AJCC v8

United States
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

Evaluation of 18F-TFB PET/CT Scan in Patients With Differentiated Thyroid Cancer

Differentiated Thyroid Gland Carcinoma | Thyroid Gland Follicular Carcinoma | Thyroid Gland Papillary Carcinoma

United States
Qianfoshan Hospital

Not yet recruiting

Correlation Between TCM Syndrome Factors and TSH Changes of Thyroid Hormone Withdrawal Before Iodine Therapy in Postoperative Patients With Thyroid Cancer

Differentiated Thyroid Carcinoma | TCM Syndrome Type
Grupo Espanol de Tumores Neuroendocrinos
Gilead Sciences; MFAR

Not yet recruiting

Sacituzumab govitEcan in THYroid Cancers (SETHY)

Differentiated Thyroid Cancer | Anaplastic Thyroid Cancer

Spain
National Cancer Institute (NCI)

Completed

Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer

Refractory Differentiated Thyroid Gland Carcinoma | Unresectable Thyroid Gland Carcinoma | Refractory Thyroid Gland Papillary Carcinoma | Refractory Thyroid Gland Follicular Carcinoma | Refractory Thyroid Gland Hurthle Cell Carcinoma

United States, Canada
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer

Poorly Differentiated Thyroid Gland Carcinoma | Thyroid Gland Anaplastic Carcinoma | Unresectable Thyroid Gland Carcinoma | Metastatic Thyroid Gland Carcinoma | Stage IVB Thyroid Gland Anaplastic Carcinoma AJCC v8 | Stage IVC Thyroid Gland Anaplastic Carcinoma AJCC v8 | Stage IVA Thyroid Gland...

United States
Dana-Farber Cancer Institute
Millennium Pharmaceuticals, Inc.

Completed

A Phase I/II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer and Incurably Poorly Differentiated or Radioidodine Refractory Differentiated Thyroid Cancer

Thyroid Cancer | Differentiated Thyroid Cancer | Anaplastic Thyroid Cancer

United States
Emory University
Eisai Inc.

Terminated

Lenvatinib and Iodine Therapy in Treating Patients With Radioactive Iodine-Sensitive Differentiated Thyroid Cancer

Differentiated Thyroid Gland Carcinoma | Thyroid Gland Follicular Carcinoma | Thyroid Gland Papillary Carcinoma

United States
AffyImmune Therapeutics, Inc.

Recruiting

Study of AIC100 CAR T Cells in Relapsed/Refractory Thyroid Cancer

Anaplastic Thyroid Cancer | Relapsed/Refractory Poorly Differentiated Thyroid Cancer

United States
Shanghai Henlius Biotech

Active, not recruiting

The Efficacy and Safety of HLX208 in Advanced Anaplastic Thyroid Cancer (ATC) With BRAF V600 Mutation

Anaplastic Thyroid Cancer | ATC

China
Stanford University
Merck Sharp & Dohme LLC

Recruiting

Phase II Trial of Pembrolizumab in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer

Thyroid Cancer

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

Pembrolizumab, Chemotherapy, and Radiation Therapy With or Without Surgery in Treating Patients With Anaplastic Thyroid Cancer

Thyroid Gland Undifferentiated (Anaplastic) Carcinoma

United States
National Cancer Institute (NCI)
Exelixis

Completed

Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer

Recurrent Thyroid Gland Carcinoma | Poorly Differentiated Thyroid Gland Carcinoma | Stage I Thyroid Gland Papillary Carcinoma | Stage II Thyroid Gland Papillary Carcinoma | Stage III Thyroid Gland Papillary Carcinoma | Tall Cell Variant Thyroid Gland Papillary Carcinoma | Stage I Thyroid Gland... and other conditions

United States
M.D. Anderson Cancer Center

Recruiting

Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer

Recurrent Thyroid Gland Carcinoma | Poorly Differentiated Thyroid Gland Carcinoma | Thyroid Gland Anaplastic Carcinoma | Thyroid Gland Squamous Cell Carcinoma | Thyroid Gland Medullary Carcinoma | Thyroid Gland Papillary Carcinoma | Malignant Thyroid Gland Neoplasm

United States
Stanford University

Active, not recruiting

Abemaciclib in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer

Thyroid Cancer | Anaplastic Thyroid Cancer | Undifferentiated Thyroid Cancer

United States
Children's Hospital of Philadelphia
United States Department of Defense

Recruiting

Targeted Therapy to Increase RAI Uptake in Metastatic DTC

Pediatric Cancer | Papillary Thyroid Cancer | Differentiated Thyroid Cancer

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Active, not recruiting

Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer

Recurrent Thyroid Gland Carcinoma | Poorly Differentiated Thyroid Gland Carcinoma | Stage IV Thyroid Gland Follicular Carcinoma AJCC v7 | Stage IV Thyroid Gland Papillary Carcinoma AJCC v7 | Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7 | Stage IVA Thyroid Gland Papillary Carcinoma AJCC... and other conditions

United States
Tel-Aviv Sourasky Medical Center

Completed

The Incidence of Postoperative Re-stratification for Recurrence in Well-differentiated Thyroid Cancer - A Single Tertiary Israeli Center Experience

Papillary Thyroid Cancer | Well Differentiated Thyroid Carcinoma
Memorial Sloan Kettering Cancer Center

Active, not recruiting

PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer

Thyroid Cancer, Follicular | Thyroid Cancer | Papillary Thyroid Cancer | Poorly Differentiated Thyroid Gland Carcinoma | Follicular Thyroid Cancer | Hurthle Cell Tumor | Hurthle Cell Thyroid Neoplasia

United States
National Cancer Institute (NCI)

Active, not recruiting

Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer

Recurrent Thyroid Gland Carcinoma | Poorly Differentiated Thyroid Gland Carcinoma | Refractory Thyroid Gland Carcinoma | Stage IV Thyroid Gland Follicular Carcinoma AJCC v7 | Stage IV Thyroid Gland Papillary Carcinoma AJCC v7 | Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7 | Stage IVA Thyroid... and other conditions

United States
Medstar Health Research Institute
Pfizer

Completed

Sutent Adjunctive Treatment of Differentiated Thyroid Cancer (IIT Sutent)

Papillary Thyroid Cancer | Differentiated Thyroid Cancer | Follicular Thyroid Cancer

United States
Fifth Affiliated Hospital, Sun Yat-Sen University

Unknown

Significance of Contralateral Central Lymph Node Dissection in Unilateral cN0 Differentiated Thyroid Carcinoma.

Lymph Node Metastases | Differentiated Thyroid Carcinoma | Lymph Node Dissection

China
National Cancer Institute (NCI)

Active, not recruiting

Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery

Recurrent Thyroid Gland Carcinoma | Refractory Thyroid Gland Carcinoma | Stage III Thyroid Gland Follicular Carcinoma AJCC v7 | Stage IV Thyroid Gland Follicular Carcinoma AJCC v7 | Stage IV Thyroid Gland Papillary Carcinoma AJCC v7 | Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7 | Stage... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Iovance Biotherapeutics, Inc.

Active, not recruiting

LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas

Malignant Solid Neoplasm | Soft Tissue Sarcoma | Recurrent Ovarian Carcinoma | Triple Negative Breast Cancer | Recurrent Osteosarcoma | Refractory Osteosarcoma | Bone Sarcoma | Giant Cell Tumor of Bone | Ovarian Carcinosarcoma | Platinum-Resistant Ovarian Carcinoma | Dedifferentiated Chondrosarcoma | Malignancy... and other conditions

United States
Istituti Clinici Scientifici Maugeri SpA
Merck Sharp & Dohme LLC

Recruiting

Pembrolizumab in High-risk Thyroid Cancer (NePenThe)

Differentiated Thyroid Cancer

Italy
National Taiwan University Hospital

Recruiting

Compare the Effects of NLSCP and Interactive ICT Supported HAP on Differentiate Diagnosed Thyroid Cancer Patients

Differentiated Thyroid Cancer

Taiwan

Clinical Trials on Differentiated Thyroid Carcinoma (DTC)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Chile

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations